Neurofibrosarcoma Pipeline Appears Robust With 15+ Key Pharma Companies Actively Working in the Therapeutics Segment
DelveInsight's, "Neurofibrosarcoma Pipeline Insight 2025,' report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Neurofibrosarcoma pipeline landscape. It covers the Neurofibrosarcoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Neurofibrosarcoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Stay ahead with the latest insights! Download DelveInsight's comprehensive Neurofibrosarcoma Pipeline Report to explore emerging therapies, key Neurofibrosarcoma Companies, and future Neurofibrosarcoma treatment landscapes @ Neurofibrosarcoma Pipeline Outlook Report
Key Takeaways from the Neurofibrosarcoma Pipeline Report
In April 2025, University of Florida conducted a phase 2, open label, single arm study will investigate the use of tazemetostat in patients with recurrent/refractory and/or metastatic malignant peripheral nerve sheath tumors.
In April 2025, Alexander Z. Wei, MD announced a phase II clinical trial will evaluate the safety and efficacy of adding APX005M (a CD40 agonistic monoclonal antibody) to doxorubicin for the treatment of patients with advanced soft tissue sarcoma. The investigators believe that doxorubicin, which is currently the standard of care for most advanced sarcomas, could work better when combined with APX005M, which is a type of immunotherapy.
DelveInsight's Neurofibrosarcoma Ppipeline report depicts a robust space with 15+ active players working to develop 15+ pipeline therapies for Neurofibrosarcoma treatment.
The leading Neurofibrosarcoma Companies such as Daiichi Sankyo, Chia Tai Tianqing Pharmaceutical Group, Mirati Therapeutics, Astex Pharmaceuticals, Ascentage Pharma Group, Apexigen, Nobelpharma, Pfizer, SpringWorks Therapeutics, NFlection Therapeutics and others.
Promising Neurofibrosarcoma Pipeline Therapies such as Ganetespib, Sirolimus, everolimus, bevacizumab, Selumetinib, Tazemetostat, Dasatinib, Doxorubicin, APX005M and others.
Stay ahead with the most recent pipeline outlook for Neurofibrosarcoma. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Neurofibrosarcoma Treatment Drugs
Neurofibrosarcoma Emerging Drugs Profile
NFX-179: NFlection Therapeutics
NFX-179 is an investigational mitogen-activated protein kinase kinase (MEK) inhibitor. NFX-179 is a ""soft"" (metabolically labile) drug, which, when formulated as NFX-179 Gel for topical application, is designed to concentrate at the dermal site of action but degrade in systemic circulation, thereby significantly reducing side effects compared to systemically available MEK inhibitors.
Sirolimus: Nobelpharma
Sirolimus inhibits T lymphocyte activation and proliferation that occurs in response to antigenic and cytokine (Interleukin IL-2, IL-4, and IL-15) stimulation by a mechanism that is distinct from that of other immunosuppressants. Sirolimus also inhibits antibody production. In cells, sirolimus binds to the immunophilin, FK Binding Protein-12 (FKBP-12), to generate an immunosuppressive complex. The sirolimus: FKBP-12 complex has no effect on calcineurin activity. This complex binds to and inhibits the activation of the mammalian Target of Rapamycin (mTOR), a key regulatory kinase. This inhibition suppresses cytokine-driven T-cell proliferation, inhibiting the progression from the G1 to the S phase of the cell cycle.
The Neurofibrosarcoma Pipeline report provides insights into
The report provides detailed insights about companies that are developing therapies for the treatment of Neurofibrosarcoma with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Neurofibrosarcoma treatment.
Neurofibrosarcoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Neurofibrosarcoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Neurofibrosarcoma market.
Explore groundbreaking therapies and clinical trials in the Neurofibrosarcoma Pipeline. Access DelveInsight's detailed report now! @ New Neurofibrosarcoma Drugs
Neurofibrosarcoma Companies
Daiichi Sankyo, Chia Tai Tianqing Pharmaceutical Group, Mirati Therapeutics, Astex Pharmaceuticals, Ascentage Pharma Group, Apexigen, Nobelpharma, Pfizer, SpringWorks Therapeutics, NFlection Therapeutics and others.
Neurofibrosarcoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Oral
Intravenous
Subcutaneous
Neurofibrosarcoma Products have been categorized under various Molecule types such as
Small molecule
Cell Therapy
Peptides
Polymer
Small molecule
Gene therapy
Unveil the future of Neurofibrosarcoma Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Neurofibrosarcoma Market Drivers and Barriers
Scope of the Neurofibrosarcoma Pipeline Report
Coverage- Global
Neurofibrosarcoma Companies- Daiichi Sankyo, Chia Tai Tianqing Pharmaceutical Group, Mirati Therapeutics, Astex Pharmaceuticals, Ascentage Pharma Group, Apexigen, Nobelpharma, Pfizer, SpringWorks Therapeutics, NFlection Therapeutics and others.
Neurofibrosarcoma Pipeline Therapies- Ganetespib, Sirolimus, everolimus, bevacizumab, Selumetinib, Tazemetostat, Dasatinib, Doxorubicin, APX005M and others.
Neurofibrosarcoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Neurofibrosarcoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Which companies are leading the race in Neurofibrosarcoma Drug development? Find out in DelveInsight's exclusive Neurofibrosarcoma Pipeline Report—access it now! @ Neurofibrosarcoma Emerging Drugs and Major Companies
Table of Contents
Introduction
Executive Summary
Neurofibrosarcoma: Overview
Pipeline Therapeutics
Therapeutic Assessment
Neurofibrosarcoma– DelveInsight's Analytical Perspective
Late Stage Products (Phase III)
Sirolimus: Nobelpharma
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
ASTX727: Astex Pharmaceuticals
Drug profiles in the detailed report…..
Early Stage Products (Phase I/II)
MRTX1719: Mirati Therapeutics
Drug profiles in the detailed report…..
Preclinical Stage Products
Drug name: Company name
Drug profiles in the detailed report…..
Inactive Products
Neurofibrosarcoma Key Companies
Neurofibrosarcoma Key Products
Neurofibrosarcoma- Unmet Needs
Neurofibrosarcoma- Market Drivers and Barriers
Neurofibrosarcoma- Future Perspectives and Conclusion
Neurofibrosarcoma Analyst Views
Neurofibrosarcoma Key Companies
Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/neurofibrosarcoma-pipeline-insight
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CTV News
42 minutes ago
- CTV News
‘Serious health risks': Health Canada warns against recreational use of laughing gas
Health Canada issues a warning for recreational use of laughing gas - nitrous oxide - over "serious health risks." (Pexels/Stephen Andrews) Health Canada is warning people not to inhale nitrous oxide, commonly known as laughing gas, recreationally due to 'serious health risks, including death.' The health agency is aware that some of these products – labelled 'whip cream chargers' in various flavours – are being sold online and in retail stores. Several unauthorized products have been seized by the agency with the help of border authorities, in order to stop unauthorized shipments from entering the country. 'Advertising and selling nitrous oxide products for inhalation to the public is strictly prohibited,' Health Canada said in a safety alert. Nitrous oxide is a drug that can only be administered by an authorized health-care professional for sedation and pain relief during medical and dental procedures, the health agency says. When inhaled – or 'huffed' – laughing gas can cause serious adverse effects like increased heart rate, loss of consciousness, low blood pressure and lack of oxygen in the body, or asphyxia. It can cause issues like anemia and vitamin B12 deficiency, as well as birth defects, blood clots in the limbs and lungs, and air leaks between the lungs and chest wall. Other potential heart impacts include palpitations, heart attack and stroke. Nitrous oxide can damage nerves and contribute to spinal cord degeneration, as well as impair bladder and bowel functions, coordination while walking and sensation in the limbs and extremities. Confusion and delusion, agitation, hallucinations, feelings of paranoia and depression may also occur, and among the most serious health effects are prolonged pain, permanent paralysis and even death. Health Canada says prolonged use of the drug could result in lasting neurological damage, even after the usage has been stopped. Additionally, it can also result in addiction and withdrawal symptoms. In the case of inhalation, the health agency has advised seeking immediate medical attention from a health-care provider. 'Health Canada strongly advises that consumers not inhale any nitrous oxide products for recreational purposes,' the notice reads.
Globe and Mail
an hour ago
- Globe and Mail
'(Build) The Biggest, Baddest CPU': Intel Stock (NASDAQ:INTC) Notches up Despite Ironic Twist
This might have been the unkindest cut that chip stock Intel (INTC) could have received. Sure, yesterday and its potential loss of CHIPS Act funding was a low blow, no mistake there, but it only got worse as new reports revealed that several Intel staffers were leaving Intel to do exactly what Intel would have needed them to do: build the 'biggest, baddest CPU' around. Shareholders took the news well, though, and sent shares up fractionally in Friday afternoon's trading. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Four of Intel's biggest names in research—who together had a combined experience of almost a century at Intel—departed the company in a plan to build a totally new kind of microprocessor. They will be using a kind of architecture that is completely different from Intel's, reports note, and in the process, hopefully show up their former bosses in the process. The four started their own company, called AheadComputing, and is working on an open style of architecture known as Reduced Instruction Set Computer – V, or RISC-V. The result, AheadComputing hopes, will be a processor that does fewer things than the current processor concept, but does this comparative handful of things better than the current processor does them. Essentially, reports note, the four are risking that AheadComputing—a vastly smaller company—will be able to move faster and better than Intel. Given Intel's new 'risk-averse' nature that we discovered yesterday with the 50% gross profit concept, they may not be wrong. But what has Intel missed out on in the process? Roadmapping an Uncertain Future But life goes on at Intel, reports note, and word notes that the Intel Foundry Direct Connect 2025 event is showing off its roadmaps and its partnerships. Intel Foundry, of course, is the chip manufacturing portion of Intel, and the one which has perhaps come under the most fire of late. But Intel looks to start delivering under the 18A process this year, and that should go a long way toward re-establishing Intel's dominance as a chip maker. Naturally, it is unclear as yet how much capacity 18A will have overall, and how much of that capacity can go to making other companies' chips. Early word suggests that everything is on schedule, so that will, at least, not be a problem. And with 14A and 14A-E waiting in the wings, it is entirely possible that Intel may be able to keep the streak going and come out ahead in the end. Is Intel a Buy, Hold or Sell? Turning to Wall Street, analysts have a Hold consensus rating on INTC stock based on two Buys, 25 Holds and four Sells assigned in the past three months, as indicated by the graphic below. After a 34.97% loss in its share price over the past year, the average INTC price target of $21.29 per share implies 5.63% upside potential. See more INTC analyst ratings Disclosure Disclaimer & Disclosure Report an Issue
Globe and Mail
an hour ago
- Globe and Mail
Got $3,000? 1 Artificial Intelligence (AI) Stock to Buy and Hold for the Long Term.
The artificial intelligence (AI) boom is showing no signs of letting up. Executive teams want to leverage this technology, while employees are worried about how it could affect their jobs. And then there are investors that continue to look for ways to profit from this trend. Picking the right business could be a boon for your portfolio. If you have $3,000 ready to invest right now, here's one AI stock to buy and hold for the long term. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue » At the forefront of AI "We will move from mobile-first to an AI-first world," CEO Sundar Pichai of Alphabet 's (NASDAQ: GOOGL)(NASDAQ: GOOG) then-Google division said in the company's 2015 letter to shareholders. This was to outline a fresh strategic focus and outlook of the tech landscape. Looking back with the benefit of hindsight, it's quite remarkable how prescient this perspective was. If we go even further back, Google was using machine learning capabilities in 2001 to help users with their spelling within its popular search engine. While everyone else seems to finally be coming around to the AI craze, Alphabet has been working on this technology for quite some time. This has become more notable recently, with different platforms leveraging AI to better serve users. For example, Search allows users to conduct queries with their cameras, Maps uses AI to provide traffic info, and YouTube can come up with captions for content creators. These are clear examples of AI helping improve the user experience. At its developer conference in May, one notable update that Alphabet announced was Agent Mode. Soon to be released, this tool can handle complex, multistep tasks from start to finish by conducting different activities like surfing the web or doing deep research. Waymo, Alphabet's autonomous vehicle (AV) and robotaxi unit, also leans heavily on AI when completing rides and ensuring a safe trip. It's also used for training and advancing the AV tech. Perhaps no segment has a greater opportunity in AI than Google Cloud. Cloud computing is a major growth market, as more IT spending shifts from on-site to off-premises. This has provided a tailwind. However, now that more companies are realizing that they must incorporate AI within their own operations, it makes Google Cloud even more critical as a vendor. During the first quarter of 2025, 74% of Alphabet's revenue, or $67 billion, came from digital advertising efforts. AI is helping these important customers by building automated ad campaigns in a budget-friendly way, for example. Alphabet is undoubtedly all-in on the AI transition. It's working on this technology to not only improve its existing products and services, but to create entirely new tools for users and customers to benefit from. That strategic focus positions it well for the future. Other reasons to buy this AI stock Based on these factors, it's understandable if you're starting to think that Alphabet might be the best AI stock to own. However, there are other reasons to appreciate this business and opportunity. Alphabet is in incredible financial shape. Even after sizable capital expenditures of $53 billion were made in 2024, the company still managed to bring in $73 billion in free cash flow. It generates unbelievable earnings that allow it to keep plowing more money into things like servers and data centers. Critics will say that this is wasteful spending, but it's a risk worth taking to ensure the business stays ahead of the curve. The current valuation is also too hard to ignore. As of this writing, shares are trading at a forward price-to-earnings ratio of 17.5. This multiple represents a 22% discount to the overall S&P 500. All this means investing $3,000 in the stock today and holding for the long term is a smart move. Should you invest $1,000 in Alphabet right now? Before you buy stock in Alphabet, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Alphabet wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $669,517!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $868,615!* Now, it's worth noting Stock Advisor 's total average return is792% — a market-crushing outperformance compared to171%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of June 2, 2025
